CA
NZ
UK
AU
IND
US
…
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Income before tax | -124.24M | -352.45M | 6.12M | -4.54M | -0.79M |
| Minority interest | -0.24M | 0.24M | - | - | - |
| Net income | -105.14M | -337.26M | 10.89M | -4.68M | -0.79M |
| Selling general administrative | 108.23M | 82.44M | 30.38M | 16.98M | 9.53M |
| Selling and marketing expenses | 19.09M | 16.65M | 3.52M | 3.37M | 2.91M |
| Gross profit | 165.44M | 157.21M | 30.16M | 18.24M | 12.92M |
| Reconciled depreciation | 54.72M | 49.32M | 6.27M | 3.93M | 2.72M |
| Ebit | -14.86M | -27.45M | 1.53M | -3.06M | -0.15M |
| Ebitda | 39.86M | -37.42M | 7.80M | -3.05M | -0.14M |
| Depreciation and amortization | 54.72M | -9.97M | 6.27M | 0.01M | 0.01M |
| Non operating income net other | - | -59.29M | 13.42M | - | - |
| Operating income | -81.46M | -27.45M | 1.53M | -3.06M | -0.15M |
| Other operating expenses | 587.52M | 575.10M | 95.22M | 63.53M | 43.77M |
| Interest expense | 43.02M | 29.70M | 1.68M | 1.49M | 0.64M |
| Tax provision | -19.34M | -15.19M | -4.78M | 0.15M | 0.00M |
| Net interest income | -43.02M | -29.70M | -1.68M | -1.49M | -0.64M |
| Non recurring | - | 236.00M | 1.48M | - | - |
| Income tax expense | -19.34M | -15.19M | -4.78M | 0.15M | 0.00M |
| Total revenue | 572.42M | 547.66M | 89.61M | 60.47M | 43.62M |
| Total operating expenses | 180.54M | 184.66M | 35.77M | 21.30M | 13.07M |
| Cost of revenue | 406.98M | 390.44M | 59.45M | 42.23M | 30.70M |
| Total other income expense net | -66.13M | -325.00M | 4.58M | -1.48M | -0.63M |
| Net income from continuing ops | -104.90M | -337.26M | 10.89M | -4.68M | -0.79M |
| Net income applicable to common shares | - | -337.02M | 10.89M | -4.68M | -0.79M |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Total assets | 856.53M | 962.90M | 321.86M | 61.59M | 41.98M |
| Intangible assets | 308.43M | 345.89M | 24.23M | 4.26M | 2.87M |
| Other current assets | 33.41M | 8.25M | 3.13M | 2.37M | 1.20M |
| Total liab | 588.04M | 603.13M | 216.73M | 54.00M | 31.27M |
| Total stockholder equity | 269.15M | 360.37M | 105.13M | 7.60M | 10.71M |
| Deferred long term liab | - | 77.03M | 0.34M | - | - |
| Other current liab | 25.78M | 35.80M | 8.94M | 2.86M | 2.97M |
| Common stock | 6.41M | 6.36M | 3.94M | 2.71M | 2.59M |
| Capital stock | 6.41M | 6.36M | 3.94M | 2.73M | 2.62M |
| Retained earnings | -453.28M | -348.28M | -11.02M | -21.91M | -17.10M |
| Other liab | - | 83.46M | 0.82M | 0.14M | - |
| Good will | 94.29M | 157.82M | 51.93M | 4.37M | 3.62M |
| Other assets | - | 7.45M | 0.28M | 8.94M | 0.23M |
| Cash | 35.49M | 18.52M | 138.92M | 1.41M | 0.61M |
| Total current liabilities | 132.19M | 164.10M | 55.11M | 31.64M | 17.48M |
| Current deferred revenue | 55.62M | 68.64M | 26.61M | 11.39M | 6.73M |
| Net debt | 382.15M | 367.98M | 35.27M | 35.01M | 16.03M |
| Short term debt | 18.23M | 30.96M | 13.39M | 14.20M | 2.85M |
| Short long term debt | 7.95M | 22.98M | 11.40M | 8.60M | 2.83M |
| Short long term debt total | 417.64M | 386.49M | 174.19M | 36.41M | 16.63M |
| Other stockholder equity | 715.70M | 707.79M | 112.20M | 26.77M | 25.18M |
| Property plant equipment | - | 186.20M | 47.98M | 37.51M | 22.83M |
| Total current assets | 213.80M | 232.98M | 189.02M | 15.30M | 12.42M |
| Net tangible assets | - | -143.34M | 28.97M | -1.06M | 4.17M |
| Net receivables | 87.38M | 100.07M | 28.36M | 10.82M | 9.52M |
| Long term debt | 369.80M | 330.68M | 154.21M | 18.83M | 13.77M |
| Inventory | 56.10M | 71.44M | 0.60M | 0.70M | 1.09M |
| Accounts payable | 32.56M | 28.70M | 6.16M | 3.20M | 4.94M |
| Noncontrolling interest in consolidated entity | - | -0.61M | - | - | - |
| Accumulated other comprehensive income | 0.33M | -5.50M | - | - | -32.88M |
| Common stock total equity | - | 6.36M | 3.94M | 2.71M | 2.59M |
| Retained earnings total equity | - | -348.28M | -11.02M | - | - |
| Non currrent assets other | 10.08M | 7.52M | 0.28M | 0.16M | 0.08M |
| Non current assets total | 642.73M | 729.92M | 132.84M | 46.29M | 29.56M |
| Capital lease obligations | 39.90M | 32.84M | 8.58M | 8.98M | 0.04M |
| Long term debt total | - | 330.68M | 154.21M | - | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Investments | -28.75M | -333.72M | -54.06M | -10.13M | -8.15M |
| Change to liabilities | - | 6.62M | 7.72M | 2.27M | 2.17M |
| Total cashflows from investing activities | - | -333.72M | -54.06M | -10.13M | -8.15M |
| Net borrowings | - | 224.99M | 131.90M | 9.74M | 6.29M |
| Total cash from financing activities | 15.87M | 203.15M | 198.83M | 9.64M | 6.21M |
| Change to operating activities | - | 0.84M | 4.32M | -1.28M | 0.74M |
| Net income | -104.90M | -337.26M | 10.89M | -4.68M | -0.79M |
| Change in cash | 16.51M | -137.94M | 155.52M | 0.80M | -0.17M |
| Begin period cash flow | 18.98M | 156.92M | 1.41M | 0.61M | 0.77M |
| End period cash flow | 35.49M | 18.98M | 156.92M | 1.41M | 0.61M |
| Total cash from operating activities | 27.88M | -5.22M | 10.75M | 1.29M | 1.78M |
| Issuance of capital stock | - | 0.00M | 48.97M | - | - |
| Depreciation | 54.72M | 49.32M | 6.27M | 3.93M | 2.72M |
| Other cashflows from investing activities | - | -333.72M | -54.06M | - | - |
| Change to inventory | 14.01M | -35.20M | 0.10M | 0.40M | 0.09M |
| Change to account receivables | 9.55M | -23.84M | -11.95M | -0.62M | -3.09M |
| Sale purchase of stock | - | 0.12M | 49.22M | - | - |
| Other cashflows from financing activities | 41.03M | 262.78M | 154.50M | 37.13M | 35.86M |
| Change to netincome | - | 302.05M | -2.84M | 0.05M | 0.12M |
| Capital expenditures | 27.50M | 36.30M | 12.47M | 6.20M | 6.88M |
| Change receivables | - | -23.84M | -11.95M | - | - |
| Cash flows other operating | - | 25.51M | 0.56M | - | - |
| Cash and cash equivalents changes | - | -135.79M | 155.52M | - | - |
| Change in working capital | 16.96M | -40.28M | 9.64M | 0.95M | -0.09M |
| Stock based compensation | 7.84M | 24.20M | 1.79M | 0.54M | 0.28M |
| Other non cash items | 79.08M | 316.63M | -12.86M | 0.36M | -0.34M |
| Free cash flow | 0.38M | -41.52M | -1.73M | -4.91M | -5.10M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc |
-29.22 4.14% |
676.94 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-8.59 3.66% |
226.34 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
26.96 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
0.44 1.75% |
25.55 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
2701 Kent Avenue, West Lafayette, IN, United States, 47906
765 463 4527
1955
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert W. Leasure Jr. | Pres, CEO & Director | 1960 |
| Ms. Beth A. Taylor CPA | Sr. VP of Fin. & CFO | 1965 |
| Dr. John E. Sagartz D.V.M., DiplomateACVP, DVM, Ph.D. | Chief Strategy Officer & Director | 1965 |
| Dr. Peter T. Kissinger | Founder, Chairman Emeritus & Scientific Advisor | 1945 |
| Mr. Brennan Freeman | VP of Fin., Principal Accounting Officer & Corp. Controller | 1987 |
| Mr. Mo Dastagir | Chief Technology Officer | 1977 |
| Ms. Fernanda Beraldi | Gen. Counsel & Corp. Sec. | NA |
| Ms. Kimberly Beaty | Sr. Director of Marketing | NA |
| Mr. William D. Pitchford | Chief HR Officer | 1955 |
| Mr. John Gregory Beattie DSA | Chief Operating Officer of Discovery and Safety Assessment | 1967 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.55%
Communication Services
-0.77%
Consumer Cyclical
-1.05%
Consumer Defensive
-0.33%
Energy
-2.55%
Financial Services
-1.62%
Financials
-0.80%
Healthcare
-2.85%
Industrials
-2.47%
Real Estate
-0.85%
Technology
-5.38%
Utilities
-0.83%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+31.04%
Please wait processing your request...